Condition
Cardiac Remodeling
Total Trials
6
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed4
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07519434Completed
AI-ECG for Time-Resolved Prediction of HFrEF
NCT07456722Not Yet Recruiting
Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia
NCT06901609Active Not Recruiting
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
NCT03274752Phase 2CompletedPrimary
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction
NCT01213251Phase 2Completed
Post-Myocardial Infarction Remodeling Prevention Therapy
NCT01676285Phase 3Completed
Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
Showing all 6 trials